NCT00821314

Brief Summary

Importance of the problem OAB is a common health problem. Milsom et al. \[1\] randomly selected a population from six European countries. From this population, 17% of the respondents reported having OAB symptoms with 14% reporting frequency, 9% urgency, and 6% urge incontinence. The study by Milsom et al. \[1\] showed that OAB adversely affected the lives of the majority (65%) of the respondents who reported OAB symptoms. Chen et al. \[2\] also reported that the prevalence of OAB in Taiwanese women was similar to that of Western women. In the study of Chen et al.\[2\], the prevalence of OAB was 18.6% for the patients; perceptions and the number of OAB condition significantly increased in the elderly women (over 65 years old, 39.3%). Apart from impairing the physical health, OAB may have a tremendous effect on psychological and social well-being. Information on the symptoms and disease severity can yield important information that often complements objective measures. Incontinence, increased urge and increased frequency of micturition affect nearly 100 million people in the western world (33 million in the US and 66 million in the European Union). These conditions are not life threatening but they seriously affect quality of life and ability to work. OAB is in some studies reported to have an incidence of up to 17 % in the western population with great consequences for the quality of life. Economic cost The total economic cost of this group of conditions is high. In 2002 the costs in the US were approximately $12.7 billion\[1\] (estimated to be $17 billion and €22 billion/year in 2005). Approximately 25% of this expenditure is spent on treatment (drug therapy, clinical consultation and surgery). Of those who suffer only 28% have sought help and only half of those currently receive treatment. Less than 3% regain long lasting normal control. Therefore, these costs are an under-estimate and the problem is large. Aetiology

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 12, 2009

Completed
1 day until next milestone

First Posted

Study publicly available on registry

January 13, 2009

Completed
3 months until next milestone

Study Start

First participant enrolled

April 1, 2009

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2010

Completed
Last Updated

June 16, 2010

Status Verified

June 1, 2010

Enrollment Period

1.7 years

First QC Date

January 12, 2009

Last Update Submit

June 15, 2010

Conditions

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The study population consists of two groups. One group consist of patients with OAB. The second group consist of volunteers without micturition complaints. (25 male \& 25 female) The second group of patients with OAB. (25 male\& 25 female) Both groups will be subjected to the exact same protocol.

You may qualify if:

  • OAB must be diagnosed by their urologist using the criteria of more than 8 micturitions on three consecutive days of these three days they keep a micturation diary with a VAS score for urge sensation.
  • Patients should have at least one episode of urge.

You may not qualify if:

  • Patients with congestive heart disease and patients with a history of heart failure.
  • Patients with a post voiding residual volume of more than 100 cc.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Maastricht University Hospital

Maastricht, Limburg, 6202 AZ, Netherlands

RECRUITING

Study Officials

  • Mohammad S Rahnama'i', MD

    University hospital Maasticht

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Mohammad S Rahnama'i, M.D.

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER

Study Record Dates

First Submitted

January 12, 2009

First Posted

January 13, 2009

Study Start

April 1, 2009

Primary Completion

December 1, 2010

Last Updated

June 16, 2010

Record last verified: 2010-06

Locations